

ASX ANNOUNCEMENT

ADMEDUS SUCCESSFULLY COMPLETES \$8.3M RIGHTS ISSUE

- Strong support received from existing shareholders for the Rights Issue to raise \$8.3M with applications for \$5.7M received
- Rights Issue fully underwritten by Patersons Securities Limited
- Follows successful completion of a \$10M placement on 5 August 2016
- Company emerges in a strong financial position to support its growth profile

Brisbane, Australia 2 September 2016

Admedus Limited (ASX: AHZ) today announces the successful completion of its fully underwritten 1 for 9 renounceable Rights Issue priced at \$0.33 which closed on the 29th of August 2016 (**Offer**). The Offer was open to eligible shareholders as of the Record Date, the 12th of August 2016. Shareholders that applied for additional shares to their entitlement will be allocated their full applications.

“The Board and I thank shareholders for their support during the Rights Issue. This places the Company in a strong financial position as we pursue growth objectives. We are looking forward to driving the Company forward and building a global healthcare Company” stated Chair and interim CEO Mr Wayne Paterson.

Along with the \$10M placement, Admedus has now raised a total of \$18.3M, before costs, ensuring the Company emerges with a strong balance sheet for future growth. The funds raised will be used to:

- make improvements in the manufacturing division to increase yields and gross margins on the regenerative tissue range;
- expand the regenerative tissue range, including the release of new products into the market this financial year;
- refine the R&D portfolio with a focus on products that are near to market; and
- fund new market expansion across emerging markets and new product ranges.

Patersons Securities Limited acted as Lead Manager and Underwriter to the Offer. Valid applications for the Offer totalled circa \$5.7M, with the balance of the Offer being placed by Patersons Securities Limited in accordance with the Underwriting Agreement.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited
Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC
Melody A. Carey
+1 917 322 2571
mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com